Windtree Therapeutics will be delisted from the Nasdaq Stock Market on August 21, 2025, after failing to meet minimum bid price requirements. The company is transitioning to over-the-counter (OTC) trading instead. This delisting follows a controversial decision to implement a significant BNB treasury strategy earlier this year. As a result of this strategy, Windtree’s stock plummeted by nearly 77%, while the cryptocurrency BNB soared to record highs. This underscores the volatile market dynamics and risks associated with integrating crypto assets into traditional financial strategies. Despite this delisting, Windtree maintains its business operations but will face challenges in maintaining liquidity and transparency for investors, which is a significant concern for other firms considering similar strategies.